

Media Release

Basel/Zurich, July 22, 2015

The Swiss biotech company Memo Therapeutics AG closes a series A financing round of 2.3 million Swiss Francs to develop and validate its MemoMAB™ antibody discovery platform

Series A financing round

Memo Therapeutics AG today announced the successful completion of its series A financing round of 2.3 million Swiss Francs which has been raised from Swiss investors (including EVA Basel, Redalpine Venture Partners and Zürcher Kantonalbank). The funds will be used to develop and validate its MemoMAB™ antibody discovery platform. MemoMAB™ will be used for discovery of novel human-derived antibodies and of antibodies against difficult targets from animals.

About MemoMAB™

The technological core of Memo Therapeutics is MemoMAB™ – a technology enabling cost and time-efficient molecular cloning and recombinant expression of the complete antibody repertoires of human and animal species. MemoMAB™ utilizes nanoliter reactor technology to increase throughput and performance of biological assays.

About Memo Therapeutics

Memo Therapeutics AG is a Basel/Zurich based Swiss biotech start-up company. It is a spin-off from the ETH Zurich, Switzerland.

For further enquiries, please contact:

Dr. Armin W. Mäder, CEO

media@memo-therapeutics.com

www.memo-therapeutics.com

Memo Therapeutics AG, c/o BPL D-BSSE ETH, Mattenstrasse 26, 4058 Basel, Switzerland.